CHADDS FORD, Pa. (AP) ¿ Drug developer Endo Pharmaceuticals Holdings Inc. said Thursday its third-quarter profit plunged on charges mainly related to the buyout of Indevus Pharmaceuticals Inc.

Net income dropped 25 percent to $49.4 million, or 42 cents per share, from $66 million, or 55 cents per share, during the same period a year prior. Revenue rose 14 percent to $361 million from $316.8 million.

Excluding charges mainly related to Indevus, the company earned 63 cents per share in the latest quarter. In February, the company paid $370 million for Lexington, Mass.-based Indevus.

Analysts polled by Thomson Reuters expected profit of 64 cents per share on revenue of $365.3 million.

Sales of the Lidoderm pain patch dipped less than 1 percent to $193 million, while sales of the pain drugs Opana and Opana ER rose 42 percent to $59 million. Revenue from the painkiller Percocet was flat at $31 million.

Generic drug sales, meanwhile, edged up less than 1 percent to $23 million.

The company raised its 2009 forecast for adjusted profit to a range of $2.67 to $2.73 per share, up from a prior range of $2.59 to $2.67 per share. It now expects revenue between $1.44 billion and $1.47 billion, up from a previous forecast of $1.39 billion to $1.44 billion.

Analysts expect full-year profit of $2.71 per share on revenue of $1.45 billion.

Copyright 2009 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

More from Technology

Throwback Thursday: Intel Edition

Throwback Thursday: Intel Edition

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

Intel CEO's Surprise Exit Leaves 'Large Void' That Won't Be Easy to Fill

Intel CEO's Surprise Exit Leaves 'Large Void' That Won't Be Easy to Fill

The Winners and Losers in Thursday's Market

The Winners and Losers in Thursday's Market

Will Porsche's Electric Car Push Take Down Tesla?

Will Porsche's Electric Car Push Take Down Tesla?